Evernow Offers Free Fda-Approved Vaginal Estrogen With Membership For Women Over 40

Oct. 10, 2025, 2:09 p.m.

Tags: estrogen

Women over 40 who are experiencing genitourinary symptoms of menopause (GSM), such as vaginal dryness, painful sex, urinary urgency or incontinence, and frequent UTIs now have a new option to access treatment at no cost. Evernow, a digital concierge health platform, recently launched a free vaginal estrogen offer for its members. This new initiative is part of a 3- or 12-month membership plan that provides ongoing access to FDA-approved vaginal estradiol, a treatment used to alleviate GSM symptoms.

The initiative is a breakthrough in women’s health, aiming to address long-standing issues of cost, stigma, and misinformation surrounding vaginal estrogen. This article explores the details of Evernow’s free estrogen offer, the rationale behind making a prescription medication available at no cost, and the clinical and financial barriers many women previously faced.

Key Details of the Free Vaginal Estrogen Offer

Evernow’s new membership model includes access to a FDA-approved, low-dose vaginal estradiol cream. The cream is described as an over-the-counter product in the program but is actually a prescription medication, suggesting that patients enrolled in the service must first consult with Evernow’s affiliated medical professionals before receiving it.

The offer is structured around multi-month memberships:

A 3-month membership or
A 12-month membership

Subscribers who sign up for either option are eligible to receive unlimited, ongoing free vaginal estradiol. The cream is made by a manufacturer approved by the U.S. Food and Drug Administration (FDA), and the product is described as safe and effective for treating vaginal atrophy associated with menopause.

The eligibility for this service appears to be broadly inclusive, with no publicly listed age, health status, or geographic restrictions directly mentioned in the provided source material. However, the stated target audience is women over the age of 40 experiencing GSM symptoms. The program is limited to the U.S., and interested parties must apply and be accepted through the Evernow platform.

The Role of Vaginal Estrogen in Menopause Care

Genitourinary symptoms of menopause (GSM) are a common but often under-discussed issue among women. In fact, studies indicate that approximately 84% of women suffer from these symptoms at some point during or after menopause. Despite its frequency, GSM tends to be overlooked during standard medical conversations, leading to prolonged discomfort and a lower quality of life.

Vaginal estrogen is a well-documented treatment for GSM and is FDA-approved for the relief of symptoms such as dryness, burning, irritation, and painful intercourse. As a low-dose, localized treatment, it works to replenish estrogen levels in the vaginal tissues, restoring moisture and elasticity. Unlike systemic estrogen therapies, which affect the entire body, vaginal estradiol is applied directly to the affected area, making it a targeted and safe option for most women.

Dr. Suzanne Gilberg-Lenz, a board-certified OB-GYN, has strongly supported this initiative, emphasizing that vaginal estradiol is not contraindicated for any woman with a vagina. She has described the lack of access to this treatment as a failure in healthcare equity.

Cost Barriers and Evernow's Free Model

One of the primary barriers to accessing vaginal estrogen has been its cost. According to the provided information, some competitors charge as much as $120 for a 3-month supply. These high costs act as a significant deterrent for many women, particularly those without robust insurance coverage or those who are underinsured. Additionally, some women may avoid treatments due to the persistent stigma around discussing intimate issues with medical professionals or pharmacies.

Evernow’s decision to provide vaginal estradiol at no cost aims to remove this financial burden, making it more viable for women to begin and continue treatment. The platform’s model appears to absorb these costs as part of its broader mission to simplify and personalize menopause care.

The cost savings are not just financial. By making the product readily available and educating women about its purpose and benefits, Evernow is addressing an underlying issue—misinformation and shame. This is particularly important given that many women may feel embarrassed or reluctant to ask for help with GSM symptoms, which are often considered "taboo."

Clinical Support and Safety

Evernow provides medical oversight for its members by connecting them with licensed healthcare professionals. This includes gynecologists and menopause specialists, who help women determine if vaginal estrogen is appropriate for their condition. These consultations are included in the membership program, which aims to personalize care while ensuring safety and efficacy.

Safety is a major concern when dealing with estrogen-based products, as estrogen, in any form, can have risks for certain individuals—especially those with a history of blood clots, certain cancers, or estrogen-sensitive conditions. However, vaginal estradiol is noted as a low-risk, localized treatment that delivers minimal systemic absorption. Medical experts consulted by the platform, such as Dr. Alicia Jackson, have affirmed that the treatment is safe and well-suited for the vast majority of women experiencing GSM symptoms.

The FDA has issued a black box warning for estrogen-based medications, but the warning relates to systemic, long-term use and does not apply specifically to localized treatments like vaginal estradiol. This distinction is emphasized in Evernow’s promotional material, and the company takes care to present the treatment as a low-risk, scientifically-backed solution.

Addressing Stigma and Improving Access

Stigma remains a significant barrier in women's health, particularly in the treatment of menopause-related conditions. Unlike erectile dysfunction treatments, which are available over the counter and discussed openly, vaginal estrogen often requires a prescription and is considered less widely accepted or normal to discuss.

Evernow has directly addressed this inequality in its promotional and news releases. Dr. Alicia Jackson, the founder of Evernow, has stated that it is time to “make vaginal care as accessible and affordable as basic skin care.” This phrase underscores the company’s vision of normalizing conversations around vaginal health and removing the stigma that has surrounded GSM treatment for decades.

By offering vaginal estradiol free of charge, along with expert medical guidance, Evernow is not only changing the financial equation—it is also contributing to a broader societal shift in how women approach and seek out menopause care.

Multi-Month Membership Benefits

The eligibility for the free estrogen cream is tied to multi-month memberships. Evernow offers two options:

A 3-month plan and
A 12-month plan

These plans include not just the provision of medication but also access to an array of menopause-related services. These include:

Regular consultations with healthcare professionals
Menopause education resources
Customized treatment plans based on individual symptoms
Ongoing monitoring and adjustments to care
Access to community support for members to connect and share experiences

While the subscription model is necessary to unlock the free estrogen cream, it is designed to provide a holistic and long-term solution to vaginal health in menopause. For many women, the convenience and affordability of an all-inclusive plan may outweigh the upfront cost of joining the program.

The program is primarily focused on the U.S. and is tailored to the needs of American women, many of whom may not have received comprehensive menopause education during their primary care visits.

The Role of Let's Talk Menopause

HELLO! Magazine, which has partnered with Evernow and Let’s Talk Menopause, is an important voice in advocating for the normalization of menopause discussions. Let’s Talk Menopause is a charitable organization dedicated to advancing women’s understanding of menopause through education, advocacy, and research.

Samara Daly, Board Chair and Co-Founder of Let’s Talk Menopause, praised Evernow’s initiative for its potential to change the landscape of midlife healthcare in the U.S. She noted that Evernow’s move aligns with the organization’s mission to support and empower women through every stage of their menopause journey.

Patient Samples and Other Initiatives

While not tied to Evernow’s free estrogen offer, some additional resources for trial access to prescription medications exist through various channels. The International Vagiscope Healthcare Foundation (IVH) is one such organization noted in the provided resources. IVH offers patient samples and educational materials related to vaginal health through its website. While it does not appear to offer free estrogen specifically, it does provide information and tools to help individuals understand and advocate for their own gynecological care.

Conclusion

Evernow’s free vaginal estradiol initiative marks a significant step forward for women’s health, particularly in the treatment and prevention of GSM symptoms during menopause. The program not only provides a low-cost or no-cost solution to access prescribed estrogen but also helps to normalize these essential treatments and reduce the stigma surrounding menopause care.

By bundling the free product with ongoing consultations, educational resources, and a supportive community, Evernow is offering a comprehensive approach to menopause that addresses both the physical and emotional aspects of the experience. This model recognizes the unique and often overlooked needs of women over 40 and positions women to take control of their health in a way that was previously harder to access or affordable.

For more information about Evernow and its free estrogen cream, women are encouraged to visit the company’s website directly.